Healthpoint Biotherapeutics Signs Brazilian Distribution Agreement For OASIS® Extracellular Matrix Product Line

FORT WORTH, Texas, June 6, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the company has entered into a distribution agreement with Efe Consultoria & Importacao Ltda to commercialize the OASIS® Extracellular Matrix product line in Brazil. OASIS® products are based on an extracellular matrix material derived from porcine small intestinal submucosa (SIS®), which is designed to support the body's natural healing mechanisms in difficult-to-heal and chronic wounds. Both single and bi-layered versions of OASIS® Extracellular Matrix will be marketed in Brazil.

SIS® is among the most widely studied and published biomaterials, featured in over 832 scientific publications. Through this partnership, Healthpoint Biotherapeutics will be able to efficiently introduce this technology to the leading wound care experts in Brazil.

"As part of our ongoing expansion of international partnerships, we are pleased to announce this distribution agreement in Brazil, our first such arrangement in an emerging BRIC market," commented Maxwell Lea, Vice President of Business Development and Corporate Finance at Healthpoint Biotherapeutics. "The timing of our entry into this market and the opportunities are both very positive considering that the Brazilian healthcare market is becoming more receptive to new technologies in the treatment of wounds."

About OASIS® Extracellular Matrix  
OASIS® Extracellular Matrix is cleared in the U.S. for the management of wounds, including surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence), partial- and full-thickness wounds, trauma wounds (including second-degree burns), venous ulcers, chronic vascular ulcers, diabetic ulcers, pressure ulcers, and draining wounds. This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material. This device is not cleared for use in third-degree burns. The OASIS® product line is marketed under the OASIS® Wound Matrix and OASIS® Ultra Tri-Layer Matrix trade names in the United States.

About Healthpoint Biotherapeutics 
Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. The company's research and development strategy is centered on next-generation bioactive therapies for the treatment of acute, chronic and burn-related wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® (becaplermin 0.01%) Gel. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®.  Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpointbio.com.

HEALTHPOINT and related logo, SANTYL, THE WOUND INSTITUTE, THEWOUNDINSTITUTE.COM and REGRANEX are registered trademarks of Healthpoint, Ltd.

OASIS is a registered trademark of Cook Biotech, Inc

SOURCE Healthpoint Biotherapeutics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED